Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 16 of 30
Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
NCT03872141
Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection
NCT03132012
Sugammadex and Decreased Time to Extubation
NCT03196167
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
NCT03023722
Saracatinib and Alcohol Drinking
NCT02955186
Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City
NCT03159299
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2
NCT03168191
Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI
NCT03084523
Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis
NCT02950077
Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial
NCT03003390
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
NCT03093155
Opioid Use Disorder in the Emergency Department: CTN 0069
NCT03023930
Imaging the Neuroimmune System in PTSD
NCT04236986
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
NCT02979977
Impact of Switching to Non-Menthol Cigarettes Among Smokers
NCT03075839
Fish Oil vs. Placebo on Subjective Effects of Alcohol
NCT03010917
New Approaches to Smoking Cessation in Heavy Drinkers
NCT02151591
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
NCT03195400
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
NCT03045341
Community Partnership for Healthy Sleep
NCT03045874
Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders
NCT02742246
Optimizing Tobacco Dependence Treatment in the Emergency Department
NCT02896400
Harnessing the Power of Technology: MOMBA for Postpartum Smoking
NCT02237898
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
NCT02784483
A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect
NCT02970656
Pivotal Response Treatment (PRT) Telemedicine
NCT03045263
Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82
NCT03048097
Novel Device for Rapid Fluid Administration
NCT03074682
Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03066193
Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ
NCT02908178
The Effect of Nicotine Delivery Rate on Reinforcement
NCT03134339
Nicotine Reinforcement and Aversion in Young Adult Light Smokers
NCT01495819
Evaluation of the Implementation and Effectiveness of IPP-HPV
NCT02994290
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
NCT03027362
Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents
NCT03107936
Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
NCT03017508
Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer
NCT03285048
Aggressive Incidents in Medical Settings Study
NCT03041272
Psilocybin for the Treatment of Cluster Headache
NCT02981173
The Neural Correlates of Cannabis Use
NCT03104257
Computer Based Training in CBT in Primary Care
NCT03013478
TAS-OX for Refractory Metastatic Colon Cancer
NCT02848079
Autism Biomarker Consortium for Clinical Trials
NCT02996669
Neuroscience of Marijuana Impaired Driving
NCT02757313
Glycemic Index of Commonly Consumed Sweeteners
NCT02931578
Neuroendocrine Response to Oral Alcohol Administration
NCT03165942
Pembrolizumab in HNSCC With Residual Disease After Radiation
NCT02892201
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
NCT02187224
A Reinforcement Approach to Increase Use of CGM
NCT02907346
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
NCT02899793
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.